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more different medications present in their pharmacy
claims data over a 3-month period were selected. Cases
were developed by combining demographic, medical, and
pharmacy claims data, and sent for review by Omnicare’s
consultant pharmacists. Based on quantitative and qual-
itative review, recommendations were made on behalf of
each retiree at moderate to high risk and the appropriate
physician contacted by telephone or fax. RESULTS: A
total of 488 polypharmacy cases were identiﬁed from a
sample of 14,000 retirees, of which 309 were eligible 
for inclusion. An average of 12 medications was pre-
scribed to these individuals. A total of 61.8% had safety,
quality, or cost issues of moderate to high risk requir-
ing intervention. In 49.1% (152) of all reviewed cases, 
medication safety issues were present. Most instances
involved an inappropriate medication for use in the
elderly. Recommendations for improved management of
coronary heart disease and stroke were addressed in
34.0% (105) and 19.4% (60) of the cases, respectively.
Other key recommendations involved aspirin use, Cox-2
Inhibitor use in retirees with heart disease, medications
associated with increased risk of falls and fractures, and
untreated osteoporosis. Recommendations were accepted
by over half of responding physicians. CONCLUSIONS:
Inappropriate medication use continues among elderly
persons treated with multiple agents. Pharmacist inter-
vention with physicians can improve prescribing in this
population.
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THE ANTIBIOTIC USE IN POLAND IN THE
TREATMENT OF COMMUNITY-ACQUIRED
PNEUMONIA IN ADOLESCENTS AND ADULTS
VERSUS CURRENT GUIDELINES
Cel M, Krzyzanowska AM, Glogowski CA, Gierczynski JM
GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland
OBJECTIVES: The aim was to compare prescription 
patterns in Poland in treatment of community-acquired
pneumonia (CAP), matched with current guidelines and
their ﬁnancial consequences. METHODS: Epidemiologi-
cal data from Alexander Project microbiological study
were used. The Dataview Medical Database IMS Health
for Poland, was the source of medical data on provided
medical services and prescriptions made out by out-
patient clinic doctors. These were compared with guide-
lines of Polish Working Group for Standards of Rational
Therapy and Prophylaxis of Infections. Drugs prices were
taken from offer of leading wholesaler. RESULTS: CAP
makes up of 4% of all respiratory system infections, 20%
of them require hospitalisation. The Alexander Project
shows that causes of CAP are: S. pneumoniae (7–76%),
H. inﬂuenzae (1–16%), S. aureus (0–4%), Gram (-) bac-
teria (0–28%), non-typical bacteria such M. pneumoniae
(0–24%) C. pneumoniae and Legionella sp. (0–15%). 
In 2002, for patients aged 12–64 years, 302.656 visits
(234.451—ﬁrst visits, 68.206—follow-up visits) because
of CAP were registered, in 254.179 (i.e. 84%) cases pre-
scriptions for antibiotics were made-out. The percentages
of antibiotics were following: 24.1% oral macrolid, 4.4%
injected macrolid, 24.2% oral cephalosporin, 16.4%
injected cephalosporin, 14.4% oral wide-spectrum peni-
cillin, 11.6% oral tetracycline, 10.2% aminoglycoside,
2.2% oral ﬂuoroquinoline, 0.2% co-trimoxasole (com-
bined treatment 7.7%). Total cost of antibiotics was
€4.549 million. For ﬁrst visits this cost amounted to
€4.043 million and for follow-up visits to €0.507 million.
The cost of treatment according to the guidelines was esti-
mated, depending on chosen option, at €3.260 to €6.713
million. CONCLUSIONS: Analysis shows that prescrip-
tion patterns in CAP, differs from the guidelines. 45% of
cases were treated in way foreseen for non-typical CAP,
whereas epidemiological data shows that real number of
such cases does not exceed 20%. Treatment based on rec-
ommendations would not bring savings, but would slow
down the growth of bacterial resistance.
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Few data have been published on the patterns of use
COX-2 inhibitors (coxibs)and non-selective NSAIDs in
“real-life” setting; a major determinant of effectiveness.
OBJECTIVES: 1) To assess the rate of persistency of
coxibs over the ﬁrst 3 months of treatment in the elderly
population; 2) to determine the rate of switching; 3) 
to identify characteristics associated with persistency.
METHODS: A retrospective cohort study was conducted
in a cumulative incidence random sample of members
(age 65+) of the Quebec drug plan who initiated a treat-
ment with celecoxib (n = 14,396), rofecoxib (n = 6,120)
or non-selective NSAIDs (n = 1,202) between January 1st
and August 31st 2000. All medical services and prescrip-
tions received by these patients during the previous year
were obtained through linkage with the Quebec health
services databases. Cox proportional hazard was used to
identify factors associated with persistency. RESULTS:
Over the ﬁrst 3 months of treatment, the median 
duration of use was 22 days for celecoxib, 21 days for
rofecoxib, and 12 days for non-selective NSAIDs. On
average, 24.2% of incident celecoxib users and 17.3% 
of rofecoxib users were treated for more than 3 months,
compared to 10.2% of non-selective NSAID users.
Switches were not frequent: 4.1% of celecoxib users
switched to rofecoxib, and 2.3% to non-selective
NSAIDs. Of rofecoxib users, 2.9% switched to celecoxib
and 2.4% to non-selective NSAIDs. Factors signiﬁcantly
associated with persistency were: celecoxib (OR = 1.19;
1.11–1.27), use of gastroprotective agents at treatment
initiation (OR = 1.22; 1.16–1.27) or during follow-up
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(OR = 1.18; 1.13–1.22), high chronic disease scores (CDS
10+: OR = 1.15; 1.10–1.20; CDS 5–9: OR = 1.13
(1.09–1.17). Previous use of gastroprotective agents,
indicative of a history of gastropathy, was negatively
associated with persistency: (OR = 0.92; 0.88–0.95). Age,
gender, dosage at initiation, prescriber’s specialty, and
income level did not inﬂuence persistency. CONCLU-
SION: Persistency beyond three months was higher for
coxibs than for non-selective NSAIDs.
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OBJECTIVES: There is a long-standing debate over the
theory that innovations (including innovative pharma-
ceuticals) are largely funded internally by companies.
Supporters of this theory assert that R&D is ﬁnanced
internally from sales, while opponents argue, that R&D
investment is unrelated to sales. The objective of this
study is to empirically test the internal funding theory for
pharmaceutical R&D and suggest policy implications
based on the results. METHODS: Data for US pharma-
ceutical sales, R&D expenditure, proﬁtability (both series
are for 1980 to 2001), and new chemical entity (NCE)
sales (all NCEs approved from 1988 to 2001) are used in
least squares time series regressions to explain variation
in annual percent change in R&D expenditure. Log-log
regressions are used to model the relationship of the
dependent variable to percent change in annual US phar-
maceutical sales and NCE 3-year future sales. A full
model also is estimated. Linear-log models of percentage
change in pharmaceutical sales are estimated for percent
return on stockholders’ equity, percent 10-year return,
and percent annual return. Series were tested for trends,
and, where appropriate, sensitivity analyses were con-
ducted on models. RESULTS: Empirical evidence from
the analyses support the hypothesis that pharmaceutical
R&D is internally funded from sales. The sales coefﬁcient
was estimated to be 1.2% (p < 0.001) and the coefﬁcient
for NCEs 3-year future sales was 0.4% (p < 0.001). When
a full model is estimated with these variables, the coefﬁ-
cients were virtually unchanged and remained statistically
signiﬁcant. Coefﬁcients for the proﬁtability model were
0.09 for percent return on stockholders’ equity, 0.05 for
10-year return, and 0.04 for annual return. CONCLU-
SIONS: The importance of sales for funding pharmaceu-
tical R&D is demonstrated. Policies detrimental to this
relationship should be expected to cause a shift of R&D
effort from the US or to reduce R&D investment in
general.
MS2
LISTENING TO OUR CONSUMERS: THE
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OBJECTIVE: Brand loyalty is an elusive, but sought after
consumer attribute. Loyalty, however, is not clearly
deﬁned; especially for pharmaceuticals that have only
recently been associated with their brands. METHODS:
Brand loyalty was assessed from a national Health care
survey, ﬁelded June 2002 to 30,000 online U.S. adults.
For this analysis, three conditions were chosen to repre-
sent a range of consumer types. Respondents (n = 7,209)
were diagnosed and taking a prescription (Rx) for: de-
pression (20% diagnosed, 51% Rx), gastroesophageal
reﬂux disease (GERD, 10% diagnosed, 64% Rx), and/or
high cholesterol (23% diagnosed, 53% Rx). Loyalty was
evaluated by summing four Health care attitudes: would
ask doctor for prescription; prescription advertising pro-
vides useful information; would ask doctor for speciﬁc
medication; and insist that doctor give brand name med-
ication. Responses were on a 5-point scale: 1 = strongly
disagree and 5 = strongly agree. Final scores ranged from
4–20 (mean = 12, standard deviation = 2.8). Loyalty was
then categorized as low (score 4–9) 18%, moderate
(10–14) 65%, and high (15–20) 16%. RESULTS: Loyal
consumers were younger, with more severe disease and
comorbid illnesses. They sought information frequently
and from more sources. Notably, loyal consumers re-
quested medications more than three times more than
those with low loyalty. Between 9–19% requested one of
their high cholesterol, depression, or GERD medications.
Requesters were more likely to be men. They had posi-
tive, proactive Health care attitudes and sought infor-
mation from a variety of sources. Notably, consumers
who requested medications remained on them up to six
months longer. CONCLUSIONS: There is a small, but
distinct group of pharmaceutical brand loyalists that is
proactive and more likely to request prescription med-
ications. Those who request medications trust doctors’
advice and stay on therapy longer. These are our target
patients. They can be reached through doctors, the inter-
net, and family and friends with the information they
need to make sound Health care decisions.
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University of York,York, United Kingdom
OBJECTIVES: To demonstrate the use of bayesian 
decision theory to establish optimal commercial drug
development programmes. METHODS: A probabilistic
model of a drug in development was used to estimate 
the expected net return of alternative development pro-
